Colchicine After Electrocardioversion for Atrial Fibrillation

• Status: Not yet recruiting
• Trial end date: 2025-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate whether a 3 month treatment course of low-dose Colchicine decreases the recurrence of Atrial fibrillation (AF) after electrocardioversion (ECV) in patients with AF.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Basel, Switzerland
• Collaborators: Fondation Machaon, Switzerland, Genf; Foundation for Cardiovascular Research Basel; Swiss Heart Foundation
• Treatments: Colchicine

Criteria

Inclusion Criteria:

• Age >18 years

• ECG-documented AF prior to ECV

• Successful ECV with conversion of AF to sinus rhythm with persistent sinus rhythm ≥1 hour after ECV

• Ability to give written informed consent

Exclusion Criteria:

• AF persistence after cardioversion or early AF recurrence within 1 hour after ECV

• Any other rhythm than AF before cardioversion

• Pulmonary vein isolation within 3 months prior to ECV or pulmonary vein isolation planned within 3 months after ECV

• Known intolerance or hypersensitivity to Colchicine

• Any other absolute indication for Colchicine intake

• Intake of a strong inhibitor of CYP3A4 or P-Glycoprotein (clarithromycin, erythromycin, telithromycin, cyclosporine, ketoconazole or itraconazole)

• Serious gastrointestinal disease (severe gastritis or diarrhea)

• Clinically overt hepatic disease

• Severe renal disease (eGFR< 30ml/min/1.73m2)

• Clinically significant blood dyscrasia (e.g., myelodysplasia)

• Significant immunosuppression (e.g. due to transplantation or rheumatic disease)

• Pregnant or breastfeeding women, or women of child-bearing potential who do not use a highly effective form of birth control

• Life expectancy <1 year